Phase III
Myovant announced that its Phase III HERO trial relugolix met its primary endpoint and six key secondary endpoints in advanced prostate cancer.
CRISPR Therapeutics and Vertex Pharmaceuticals announced positive interim data from the first two patients in the companies’ ongoing Phase I/II clinical trials of its CRISPR/Cas9 gene-editing therapy CTX001.
The results of the Phase III VICTORIA trial set up the potential for the companies to seek regulatory approval for vericiguat.
The company halted the development of the drug RTB101 for respiratory disease but will continue to test it in other areas. Look at the reasons behind the halt.
Study 2 Demonstrated that Bempedoic Acid Significantly Lowered LDL-Cholesterol and Reduced hsCRP
HES is a rare group of inflammatory disorders that affects approximately 20,000 people around the world.
The company will discontinue development of its lead T-cell asset, ATIR101, halt its ongoing Phase III trial and lay off half its staff.
Jonathan Cotliar, chief medical officer of Science 37, a leader in virtual clinical trials, took time to speak with BioSpace about virtual and hybrid clinical trials, the CNS Summit and Science 37.
Bardoxolone methyl is an experimental, oral, once-a-day activator of Nrf2, a transcription factor that induces molecular pathways involved in resolving inflammation.
Eli Lilly is planning to seek another regulatory approval for Taltz after the medication hit the primary and secondary endpoints in a Phase III study for the treatment of non-radiographic axial spondyloarthritis.
PRESS RELEASES